637 related articles for article (PubMed ID: 10070965)
1. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
2. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
Bot A; Casares S; Bot S; von Boehmer H; Bona C
J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
[TBL] [Abstract][Full Text] [Related]
3. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro.
Muraoka S
Eur J Immunol; 1991 Sep; 21(9):2095-103. PubMed ID: 1679712
[TBL] [Abstract][Full Text] [Related]
5. Co-receptor-independent signal transduction in a mismatched CD8+ major histocompatibility complex class II-specific allogeneic cytotoxic T lymphocyte.
Eshima K; Tachibana M; Suzuki H; Yamazaki S; Shinohara N
Eur J Immunol; 1997 Jan; 27(1):55-61. PubMed ID: 9021998
[TBL] [Abstract][Full Text] [Related]
6. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
7. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
[TBL] [Abstract][Full Text] [Related]
8. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
Asnagli H; Schmitt-Verhulst AM; Guimezanes A
J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
[TBL] [Abstract][Full Text] [Related]
9. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
10. Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.
Herrmann T; Maryanski JL; Romero P; Fleischer B; MacDonald HR
J Immunol; 1990 Feb; 144(4):1181-6. PubMed ID: 1968075
[TBL] [Abstract][Full Text] [Related]
11. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
12. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
13. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
14. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
15. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
16. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
18. Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice.
Lee MK; Huang X; Jarrett BP; Moore DJ; Desai NM; Moh Lian M; Markmann JW; Deng S; Frank A; Singer A; Velidedeoglu E; Caton AJ; Markmann AJ
Transplantation; 2003 Apr; 75(8):1415-22. PubMed ID: 12717241
[TBL] [Abstract][Full Text] [Related]
19. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
20. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]